Print
|
Close
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Active:
Yes
Cancer Type:
Unknown Primary
NCT ID:
NCT06467357
Trial Phases:
Phase III
Protocol IDs:
D781PC00001 (primary)
NCI-2024-08124
2023-508057-19-00
Eligibility:
18 - 99 Years, Male and Female
Study Type:
Treatment
Study Sponsor:
AstraZeneca Pharmaceuticals LP
NCI Full Details:
http://clinicaltrials.gov/show/NCT06467357
Summary
The purpose of this study is to measure the efficacy and safety of T-DXd with
rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and
durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
Treatment Sites in Georgia
Piedmont Physicians Medical Oncology
1800 Howell Mill Road
Suite 300
Atlanta, GA 30318
www.piedmont.org
Doctors:
Eyal Meiri MD
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.